Local transplant availability reduced patient travel burden and preserved continuity for long-term oncology relationships, reinforcing the program’s mission around access and community-based care.

Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung ...

Irene Flores' advocacy for bedside nurses helped build a local stem cell transplant program, making her an Extraordinary Healer Award nominee.

FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast ...

In this Q&A, Dr. Dina Khalaf, a clinical associate professor in the University of Florida Division of Hematology and Oncology ...

After having cancer, travelling can become more than a getaway. It can be part of your emotional recovery. Rest, joy, and ...

Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant ...

September is Blood Cancer Awareness Month, and the pipeline for leukemia, lymphoma and myeloma is as active as it has been in years. One CAR T-cell therapy for multiple myeloma is awaiting an FDA ...

Venesection, the term used in the United Kingdom for therapeutic phlebotomy, has long been a standard treatment for PV. The procedure removes blood to help keep red blood cell levels under control, ...

Patients in CONVERGE have stage 3 lung cancer and receive chemotherapy and radiation at the same time, followed by the immunotherapy Imfinzi (durvalumab) given by IV. Even with that treatment, fully ...

Patients with early-stage EGFR-mutated non-small cell lung cancer (NSCLC) who took Tagrisso (osimertinib) for three years ...

In the phase 3 DESTINY-Lung04 trial, patients with HER2-mutant advanced non-small cell lung cancer treated with Enhertu went ...